Monica Gandhi1, Guohong Wang2, Roger King2, Warren C Rodrigues2, Michael Vincent2, David V Glidden3, Tim R Cressey4,5,6, Peter Bacchetti3, Matthew A Spinelli1, Hideaki Okochi1, Oraphan Siriprakaisil7, Virat Klinbuayaem7, Nelly R Mugo8,9, Kenneth Ngure9, Paul K Drain10, Jared M Baeten10. 1. Division of HIV, Infectious Disease, and Global Medicine, Department of Medicine, University of California, San Francisco (UCSF), San Francisco. 2. Alere Rapid Diagnostics/Abbott Rapid Diagnostics Division (ARDx), Pomona. 3. Department of Epidemiology and Biostatistics, UCSF, San Francisco, California, USA. 4. Department of Medicine, Chiang Mai University, Chiang Mai, Thailand. 5. Department of Immunology & Infectious Diseases, Harvard T.H Chan School of Public Health, Boston, Massachusetts, USA. 6. Department of Molecular & Clinical Pharmacology, University of Liverpool, UK. 7. Sanpatong Hospital, Sanpatong, Chiang Mai, Thailand. 8. Centre for Clinical Research, Kenya Medical Research Institute (KEMRI), Thika, Kenya. 9. Departments of Global Health, Medicine and Epidemiology, University of Washington, Seattle, Washington, USA. 10. Department of Community Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Abstract
OBJECTIVE: HIV prevention and treatment studies demonstrate that pharmacologic adherence metrics are more accurate than self-report. Currently available metrics use liquid-chromatography/tandem-mass-spectrometry (LC-MS/MS), which is expensive and laboratory-based. We developed a specific and sensitive antibody against tenofovir, the backbone of treatment and prevention, but conversion to a lateral flow assay (LFA) - analogous to a urine pregnancy test - is required for point-of-care testing. We describe the development of the first LFA to measure antiretroviral adherence in real-time. METHODS: Previous work in a directly observed therapy study of providing tenofovir disoproxil fumarate (TDF) to HIV-noninfected volunteers at various simulated adherence patterns defined the appropriate cut-off for the LFA (1500 ng tenofovir/ml urine). We developed the LFA using a sample pad for urine; a conjugate pad coated with TFV-specific antibodies conjugated to colloidal gold nanoparticles; a nitrocellulose membrane striped with tenofovir-antigen (test line) and a control line; with an absorbent pad to draw urine across the reaction membrane. RESULTS: We tested 300 urine samples collected from the directly observed therapy study by this LFA and the gold-standard method of LC-MS/MS. The LFA demonstrated 97% specificity (95% CI 93-99%) and 99% sensitivity (94-100%) compared with LC-MS/MS. The LFA accurately classified 98% of patients who took a dose within 24 h as adherent. CONCLUSION: We describe the development and validation of the first point-of-care assay to measure short-term adherence to HIV prevention and treatment in routine settings. The assay is low-cost, easy-to-perform and measures the breakdown product (tenofovir) of both TDF and tenofovir alafenamide (TAF). This assay has the potential to improve HIV and PrEP outcomes worldwide by triggering differentiated service delivery with further study merited.
OBJECTIVE: HIV prevention and treatment studies demonstrate that pharmacologic adherence metrics are more accurate than self-report. Currently available metrics use liquid-chromatography/tandem-mass-spectrometry (LC-MS/MS), which is expensive and laboratory-based. We developed a specific and sensitive antibody against tenofovir, the backbone of treatment and prevention, but conversion to a lateral flow assay (LFA) - analogous to a urine pregnancy test - is required for point-of-care testing. We describe the development of the first LFA to measure antiretroviral adherence in real-time. METHODS: Previous work in a directly observed therapy study of providing tenofovir disoproxil fumarate (TDF) to HIV-noninfected volunteers at various simulated adherence patterns defined the appropriate cut-off for the LFA (1500 ng tenofovir/ml urine). We developed the LFA using a sample pad for urine; a conjugate pad coated with TFV-specific antibodies conjugated to colloidal gold nanoparticles; a nitrocellulose membrane striped with tenofovir-antigen (test line) and a control line; with an absorbent pad to draw urine across the reaction membrane. RESULTS: We tested 300 urine samples collected from the directly observed therapy study by this LFA and the gold-standard method of LC-MS/MS. The LFA demonstrated 97% specificity (95% CI 93-99%) and 99% sensitivity (94-100%) compared with LC-MS/MS. The LFA accurately classified 98% of patients who took a dose within 24 h as adherent. CONCLUSION: We describe the development and validation of the first point-of-care assay to measure short-term adherence to HIV prevention and treatment in routine settings. The assay is low-cost, easy-to-perform and measures the breakdown product (tenofovir) of both TDF and tenofovir alafenamide (TAF). This assay has the potential to improve HIV and PrEP outcomes worldwide by triggering differentiated service delivery with further study merited.
Authors: Jose R Castillo-Mancilla; Jia-Hua Zheng; Joseph E Rower; Amie Meditz; Edward M Gardner; Julie Predhomme; Caitlin Fernandez; Jacob Langness; Jennifer J Kiser; Lane R Bushman; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2012-10-10 Impact factor: 2.205
Authors: Matthew A Spinelli; David V Glidden; Peter L Anderson; Monica Gandhi; Stephanie Cohen; Eric Vittinghoff; Megan E Coleman; Hyman Scott; Oliver Bacon; Richard Elion; Michael A Kolber; Susan P Buchbinder; Albert Y Liu Journal: J Acquir Immune Defic Syndr Date: 2019-06-01 Impact factor: 3.731
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Matthew A Spinelli; David V Glidden; Warren C Rodrigues; Guohong Wang; Michael Vincent; Hideaki Okochi; Karen Kuncze; Megha Mehrotra; Patricia Defechereux; Susan P Buchbinder; Robert M Grant; Monica Gandhi Journal: AIDS Date: 2019-04-01 Impact factor: 4.177
Authors: Maureen J Kimulwo; Javan Okendo; Rashid A Aman; Bernhards R Ogutu; Gilbert O Kokwaro; Dorothy J Ochieng; Anne W T Muigai; Florence A Oloo; Washingtone Ochieng Journal: PLoS One Date: 2017-02-24 Impact factor: 3.240
Authors: Monica Gandhi; Peter Bacchetti; Warren C Rodrigues; Matthew Spinelli; Catherine A Koss; Paul K Drain; Jared M Baeten; Nelly R Mugo; Kenneth Ngure; Leslie Z Benet; Hideaki Okochi; Guohong Wang; Michael Vincent Journal: EClinicalMedicine Date: 2018-08-31
Authors: Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain Journal: Int J Infect Dis Date: 2020-06-14 Impact factor: 3.623
Authors: Matthew A Spinelli; Jessica E Haberer; Peter R Chai; Jose Castillo-Mancilla; Peter L Anderson; Monica Gandhi Journal: Curr HIV/AIDS Rep Date: 2020-08 Impact factor: 5.071
Authors: Paul K Drain; Ashley R Bardon; Jane M Simoni; Tim R Cressey; Pete Anderson; Derin Sevenler; Ayokunle O Olanrewaju; Monica Gandhi; Connie Celum Journal: Curr HIV/AIDS Rep Date: 2020-10 Impact factor: 5.071
Authors: Derin Sevenler; Xin Niu; Sandy Dossantos; Mehmet Toner; Tim R Cressey; Rebecca D Sandlin; Paul K Drain Journal: J Antimicrob Chemother Date: 2022-03-31 Impact factor: 5.758
Authors: Lauren Jennings; Tracy Kellermann; Matthew Spinelli; Zukiswa Nkantsu; Dolphina Cogill; Marije van Schalkwyk; Eric Decloedt; Gert van Zyl; Catherine Orrell; Monica Gandhi Journal: AIDS Res Hum Retroviruses Date: 2021-12-29 Impact factor: 1.723
Authors: Matthew A Spinelli; Warren C Rodrigues; Guohong Wang; Michael Vincent; David V Glidden; Hideaki Okochi; Randy Stalter; Patricia Defechereux; Madeline Deutsch; Robert M Grant; Kenneth Ngure; Nelly R Mugo; Jared M Baeten; Monica Gandhi Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771
Authors: Nicholas Thuo; Madison Polay; Anna M Leddy; Kenneth Ngure; Purba Chatterhee; Monica Gandhi; K Rivet Amico Journal: AIDS Behav Date: 2021-04-24
Authors: Kelly A Johnson; Xin Niu; David V Glidden; Jose R Castillo-Mancilla; Jenna Yager; Samantha MaWhinney; Mary Morrow; Hideaki Okochi; Tim R Cressey; Paul K Drain; Monica Gandhi; Peter L Anderson; Matthew A Spinelli Journal: Open Forum Infect Dis Date: 2021-04-17 Impact factor: 4.423